A prospective study to analyze the etiology, prevalence, clinical presentation, age and sex wise distribution of thyrotoxicosis among thyroid disorders in a tertiary care hospital

Manoj Kumar Nirmalanandan*, Kavitha Jayanthi Balachandran

INTRODUCTION

Thyroid disorders account for one of the major health problems in developing countries. India amounts to an increased number of thyroid disorders.1 Thyrotoxicosis is a clinical syndrome due to excess of circulating free thyroxine (T4) and triiodothyronine (T3) or a combination of both.2 The most common cause of hyperthyroidism, in general, are due to Graves’ disease (70-80%). Other causes include toxic thyroid adenoma, toxic multinodular goitre, and subacute thyroiditis. Overdosing of medicine resulting in thyrotoxicosis is sometimes seen.3 Symptoms of thyrotoxicosis include sweating, weight loss despite increased appetite, heat intolerance, increased thirst, menstrual disturbance, anxiety, diarrhoea, palpitation, hair loss, sleep disturbances.4 Thyrotoxicosis can be primary type presenting with symptoms related to the central nervous system. It can be a secondary type that presents with more cardiovascular system involvement such as high output cardiac failure, congestive heart failure, peripheral oedema, and arrhythmias such as ventricular tachycardia and atrial fibrillation.5,6 Graves’ disease is an autoimmune disorder presenting with painless diffuse goitre in 90%, ophthalmology in 60%
Hyperthyroidism in Graves’ disease is mediated by stimulant action of thyroid-stimulating hormone receptor autoantibodies (TSH-R) on thyrocytes. These autoantibodies bind to and activate the TSH-R and mimic the effects of thyroid-stimulating hormone (TSH) resulting in biosynthesis and secretion of thyroid hormone. It stimulates thyrocyte proliferation leading to enlargement of the thyroid gland or may block the synthesis of TSH by blocking autoantibodies. Some people develop one episode of hyperthyroidism and then go in for hypothyroidism years later. Thyroid failure occurs due to thyroid blocking antibodies and tissue destruction by cell-mediated immunity and cytotoxic antibodies.

Grave’s disease is managed medically by drugs which include carbimazole, methimazole, and propyl thio uracil depending on the situation. Treatment duration may last for usually 18 months. Complications include pruritus, arthralgia, alopecia, agranulocytosis, cholestatic jaundice, aplastic anaemia, and thrombocytopenia. The relapse rate of grave’s disease is 50% after 18 months. Beta-blockers are used to decrease clinical features such as tremor, palpitation, and anxiety. Iodine 123 (I123) isotope is used in nuclear medicine for treating Graves’ disease. It is mainly for elderly people, recurrence after using antithyroid drugs for a long period, and on whom surgery or drug treatment is contraindicated.

A high relapse rate is associated with a high concentration of TSH-R at the time of diagnosis, large goitre, and severe hyperthyroidism at the time of diagnosis. Surgery has an important role in the treatment of thyrotoxicosis after making the gland euthyroid. This is mainly for patients who are not fit for medical management or radioactive iodine treatment.

Graves’s ophthalmopathy is a dreaded complication of Graves’ disease which needs proper and planned care. Treatment includes wearing dark glasses in minor cases to artificial tears, tarsorrhaphy, and orbital decompression, and steroids in more difficult situation. Toxic nodular goitre and toxic adenoma are associated with hyper-functioning nodule detected in 131I scan which is treated by radioactive iodine or by surgery depending on considering various other factors.

The aim of the study is to analyse the etiology, prevalence, clinical presentation, age, and sex-wise distribution of Thyrotoxicosis among thyroid disorders in a tertiary care hospital. This study gives an idea about the hospital prevalence of hyperthyroidism, common age, and sex-wise distribution, the different ways of clinical presentation of thyrotoxicosis, among the thyroid disorders admitted in a tertiary care hospital which will give indirect evidence about the impact of this disease condition in the health care system.

METHODS

This is a prospective study and was set up in the Department of General Surgery, Government Medical College, Thiruvananthapuram during the period from January 2003 to December 2003. 2410 patients admitted to surgical wards with thyroid swelling were included in the study. Proper inclusion and exclusion criteria were made.

Inclusion criteria

All patients with thyroid swelling above the age of 13 years admitted to Medical College Hospital, Thiruvananthapuram during the study period were selected for the study.

Exclusion criteria

All patients below the age of 13 years, those associated with severe co-morbid conditions, patients with thyrotoxicosis treated with other modalities of management were excluded.

Selection of cases was done by senior residents with guidance from the senior faculty member in charge of the wards. All patients with thyroid swelling, who were admitted, were asked about the history related to hyperthyroidism. A clinical examination was carried out. Thyroid function test results were analysed and patients with symptoms, sign, and thyroid function test results showing hyperthyroidism were selected for the study with due importance in matching the inclusion and exclusion criteria. Ethical approval for the study was obtained from the hospital ethical committee.

With a confidence level of 95%, the sample size was calculated using the formula 4pq/l square. With p as 2, l is 20% of p which is 0.2; q will be 100-p=98. The minimum sample size was calculated to be 1960. All patients satisfying the inclusion criteria were consecutively recruited.

The data were entered in excel format in computer and the statistical analysis part was done by using the statistical program SPSS. All observations of frequency are described in percentages. The data were presented with tables, figures, and diagrams.

RESULTS

During the study period of study, of the 2410 patients who were admitted to the general ward of the surgical department with complaints of thyroid problems, 60 patients had proved features of thyrotoxicosis. The prevalence was analyzed and it was found to be 2.5% (Table 1).
Table 1: Prevalence of Thyrotoxicosis.

| No. of thyroid cases admitted | Thyrotoxicosis | Prevalence |
|------------------------------|----------------|------------|
| 2410                         | 60             | 2.5%       |

In this study, the youngest patient was 14 years old and the oldest was of 65 years. The majority of the study population was in the twenties and forties (Figure 1).

Figure 1: Age-wise distribution of patients.

Considering the total number of admission of any thyroid swelling, the female incidence is more, partly because of increased prevalence and partly because of increased cosmetic awareness among young females (Figure 2).

Figure 2: Sex-wise distribution of patients.

This distribution is having similarities with most of the reported series in our country and elsewhere. The main presenting symptoms were analyzed and palpitation was present in 96.7% of patients, swelling in the thyroid region was present in 91.6% and tremor in 88.5%. Hoarseness of voice was low and present only in 1.3%. Heat intolerance was present in 76.6%, loss of weight in 88.5%, whereas increased appetite in 68.4%. Among the female patients, menstrual irregularity was there in 26.7% (Table 2) (Figure 3).

Table 2: Symptoms and signs of thyrotoxicosis.

| Symptoms and signs                  | No. of patients | Percentage |
|-------------------------------------|----------------|------------|
| Swelling thyroid region              | 55             | 91.6       |
| Tremor                              | 53             | 88.5       |
| Heat intolerance                    | 46             | 76.6       |
| Loss of weight                      | 53             | 88.5       |
| Increased appetite                  | 41             | 68.4       |
| Palpitation                         | 58             | 96.7       |
| Menstrual Irregularity              | 16             | 26.7       |
| Hoarseness of voice                 | 1              | 1.3        |
| Hard consistency                    | 4              | 5.3        |

The different etiologies of hyperthyroidism were analyzed. Toxic multinodular goiter was the etiology in 66.8%. Graves' disease accounts for 21.4% and Toxic adenoma for 11.8% (Figure 4).

Figure 4: Etiology of thyrotoxicosis.
DISCUSSION

The prevalence of thyrotoxicosis among thyroid disorders in our study was 2.5%. In a similar study by Bose et al, the prevalence of hyperthyroidism is 1.79%, which is close to our study.14 The majority of the study population was in the twenties and forties. Female incidence was high in total admissions of thyroid swelling partly due to increased prevalence and partly due to increased cosmetic awareness among females. In another similar study by Abharam et al from Pondicherry, the prevalence was 1.8%.15 In a study by Hoogendoorn et al the prevalence of overt hyperthyroidism was 0.4% and subclinical hyperthyroidism was 0.8%.16

In a Madurai based study conducted by Velayutham et al, the prevalence of hyperthyroidism among the female population was 0.3%.17 Another study conducted by Bjuro et al, the prevalence of hyperthyroidism was 2.5% in females and 0.6% in males.18 In a meta-analysis by Madariaga et al in Europe the prevalence of hyperthyroidism was 0.8%.19 In the NHANES III survey by Hollowell et al in the USA, the prevalence of hyperthyroidism was 1.3%.20 The main presenting symptoms were palpitation (96.7%), swelling thyroid region (91.6%), tremor (88.5%), heat intolerance (76.6%), loss of weight (88.5%), increased appetite (68.4%), menstrual irregularity (26.7%), hoarseness of voice (1.3%) which was almost similar in other studies done elsewhere. The different etiologies of hyperthyroidism were also accessed; the results of which came as follows: toxic multinodular goiter was 66.8%; Graves' disease 21.4%; toxic adenoma 11.8%

Taking into consideration the prevalence of thyrotoxicosis in different studies done in other parts of the world, our prevalence of thyrotoxicosis due to hyperthyroidism is higher when compared. This study is covering only a small cross-section of society. Further studies are needed to assess the prevalence better. Financial problems, access to the health care system, cultural aspects, and apprehensions of the people may be preventing them from getting examined and tested to diagnose the problem in a wider dimension.

CONCLUSION

The prevalence of thyrotoxicosis among thyroid disorders in our study is 2.5%. The majority of the study population was in the twenties and forties. In the total number of admission of any thyroid swelling, the female incidence is more partly because of increased prevalence and partly because of increased cosmetic awareness among young females.

Hyperthyroidism and other causes of thyrotoxicosis are a real burden to the health care system in terms of financial aspects as well as morbidity to the patients.

A study on the prevalence of thyrotoxicosis among thyroid disorders is crucial as it can give an idea about the present disease burden in the hospital. This gives an idea about the plan to assess prevalence in the community. This methodology and plan of work can later be used for conducting larger studies based on the prevalence, clinical presentation, and etiology of thyrotoxicosis.

One among the limitation of the study is that, the present study is conducted in only one institution and is inpatient based. This will give only a hospital based prevalence. To get community based prevalence, the study needs to be extended to outpatient department as well as to other institutions.

By conducting such multicentre studies in a larger extend by inter-institutional data collection and wider data analysis, the consensus in the management of thyrotoxicosis can be made and can be used for the betterment of patient care in the future.

ACKNOWLEDGEMENTS

Authors would like to express their sincere gratitude to all the patients, staff, and students of Government Medical College, Thrivunanthapuram, and colleagues who helped them with this study.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: The study was approved by the Institutional Ethics Committee

REFERENCES

1. Unnikrishnan AG, Menon UV. Thyroid disorders in India: An epidemiological perspective. Indian J Endocrinol Metab. 2011;15:78-81.
2. Kravets I. Hyperthyroidism: Diagnosis and Treatment. Am Fam Physician. 2016;93(5):363-70.
3. Gilbert J. Thyrotoxicosis: investigation and management. Clin Med. 2017;17(3):274-7.
4. Blick C, Nguyen M, Jialal I. Thyrotoxicosis. StatPearls. Available at: https://www.statpearls.com/kb/viewarticle/30167. Accessed on: 20 May 2020.
5. Nygaard B. Hyperthyroidism (primary). BMJ Clin Evid. 2010. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3275323/. Accessed on: 20 May 2020.
6. Ching GW, Franklyn JA, Stallard TJ, Daykin J, Sheppard MC, Gammage MD. Cardiac hypertrophy as a result of long-term thyroxine therapy and thyrotoxicosis. Heart. 1996;75(4):363-8.
7. Chazenbalk GD, Pichurin P, Chen CR, Latrofa F, Johnstone AP, McLachlan SM, et al. Thyroid-stimulating autoantibodies in Graves disease preferentially recognize the free A subunit, not the thyrotropin holoreceptor. J Clin Invest. 2002;110(2):209-17.
8. Muehlberg T, Gilbert JA, Rao PV, McGregor AM, Banga JP. Dynamics of thyroid-stimulating and -blocking antibodies to the thyrotropin receptor in a murine model of Graves’ disease. Endocrinology. 2004;145(4):1539-45.
9. Barsouk A, Peele KA, Kiljanski J, Stolarski C, Nebes V, Kennerdell JS, et al. Antibody-dependent cell-mediated cytotoxicity against orbital target cells in thyroid-associated ophthalmopathy and related disorders: close relationship between serum cytotoxic antibodies and parameters of eye muscle dysfunction. J Endocrinol Invest. 1996;19(6):334-41.
10. McLachlan SM, Rapoport B. Thyrotropin-blocking autoantibodies and thyroid-stimulating autoantibodies: potential mechanisms involved in the pendulum swinging from hypothyroidism to hyperthyroidism or vice versa. Thyroid Off J Am Thyroid Assoc. 2013;23(1):14-24.
11. Iagaru A, McDougall IR. Treatment of thyrotoxicosis. J Nucl Med. 2007;48(3):379-89.
12. Mumtaz M, Lin LS, Hui KC, Mohd Kir AS. Radioiodine I-131 for the therapy of Graves’ disease. Malays J Med Sci MJMS. 2009;16(1):25-33.
13. Livolsi V, Baloch Z. The pathology of hyperthyroidism. Front Endocrinol. 2018;9:737.
14. Bose A, Sharma N, Hemvani N, Chitnis DS. A hospital based prevalence study on thyroid disorders in Malwa region of central India. Int J Curr Microbiol App Sci. 2015;4(6):604-11.
15. Abraham R, Srinivasa MV, Pukazhvanthen P, Sen SK. Thyroid disorders in women of Puducherry. Indian J Clin Biochem. 2009;24(1):52-9.
16. Hoogendoorn EH, Hermes AR, de Vegt F, Ross HA, Verbeek ALM, Kiemeney LALM, et al. Thyroid function and prevalence of anti-thyroid peroxidase antibodies in a population with borderline sufficient iodine intake: influences of age and sex. Clin Chem. 2006;52(1):104-11.
17. Velayutham K, Selvan SSA, Unnikrishnan AG. Prevalence of thyroid dysfunction among young females in a South Indian population. Indian J Endocrinol Metab. 2015;19(6):781-4.
18. Bjoro T, Holmen J, Krüger O, Midtbøll J, Hunstad K, Schreiner T, et al. Prevalence of thyroid disease, thyroid dysfunction and thyroid peroxidase antibodies in a large, unselected population. The Health Study of Nord-Trøndelag (HUNT). Eur J Endocrinol. 2000;143(5):639-47.
19. Madariaga AG, Palacios SS, Grima FG, Galofré JC. The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis. J Clin Endocrinol Metab. 2014;99(3):923-31.
20. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002;87(2):489-99.
21. Predicting relapse of Graves’ disease following treatment with antithyroid drugs. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4812122/. Accessed on: 21 May 2020.
22. Image Graves ophthalmopathy. Available from: https://www.google.com/search?q=image+graves+ophthalmopathy&sxsrf=ALeKk00Why4wV_UcJNhD0BkcqpuCu5Hd0g:1590171100982&source=lnms&tbm=isch&sa=X&ved=2ahUKEwiMmuz8iMjpAhUlyDgGHX9_DgEQ_AUoAXoECAsQAw. Accessed on: 22 May 2020.